Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2025-12-30 @ 2:03 PM
Study NCT ID:
NCT03534804
Status:
COMPLETED
Last Update Posted:
2024-11-26
First Post:
2018-05-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
Sponsor:
University of Utah
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
HCI104688
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |